0
0
10/16/22 at 3:00am
Organization
Mims.com
Author
Roshini Claire Anthony
45 words
0
Comments
The first interim analysis of the phase III IMpower010 trial suggests an overall survival (OS) benefit with atezolizumab compared with best supportive...
You are the first to view
https://specialty.mims.com/topic/does-atezolizumab-improve-os-in-patients-with-resected-nsclc-and-pd-l1--1-percent-
Create an account
or login to join the discussion